GLUE - Rega marang bathi kanthi panyesuaian wutah monterosatx.com

The battle for unique patents in targeted oncology is creating severe pressure on Monte Rosa Therapeutics (GLUE). The balance between the P/E multiple and growth reflects the market reaction to these risks, while the 0.00 indicator confirms the current level. Development relies on the QuEEN AI platform, and the high cost of trials combined with FDA oversight create insurmountable barriers for new entrants.

GLUE: Pangali rega marang bathi tumrap wutah monterosatx.com 04.07.2022 - 10.11.2026

Rincian metrik lan analitis perusahaan Monte Rosa Therapeutics (GLUE)

- nilai pasar lan prakiraan target analis:

Bagan kurs Monte Rosa Therapeutics Inc|GLUE - Target konsensus

- statistik kapitalisasi pasar:

Nilai pasar Monte Rosa Tx|GLUE - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data nilai buku modal saham:

Nilai Akuntansi Saham Monte Rosa Therapeutics|GLUE - Aset Bersih Perusahaan|Multiplikator Kapitalisasi Pasar marang Nilai Buku monterosatx.com|GLUE - Total Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Total Utang marang Modal Monte Rosa Therapeutics|GLUE - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal monterosatx.com|GLUE - Gunggung utang perusahaan|Utang marang aset resik Monte Rosa Tx|GLUE - Utang jangka dawa perusahaan|Utang jangka cendhak Monte Rosa Therapeutics|Rasio likuiditas perantara monterosatx.com

- informasi bathi lan kelipatan valuasi:

GLUE - Bathi resik|Bathi resik sing dikarepake Monte Rosa Therapeutics|GLUE - Pangali P/E|Rasio rega marang bathi mangsa ngarep Monte Rosa Corp|GLUE - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Monte Rosa Tx|GLUE - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Monte Rosa Therapeutics|GLUE - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan monterosatx.com|GLUE - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Monte Rosa Therapeutics

Analisis umum perusahaan:Monte Rosa Therapeutics

Monte Rosa Therapeutics (GLUE) leverages its monopoly position in the targeted protein degradation segment to establish premium pricing for its oncology drugs. The PEG ratio allows for an assessment of the fairness of market value relative to business expansion, where values below one signal an undervaluation of potential, as clearly confirmed by the historical PEG level.

Perusahaan pesaing

Genmab AS (GMAB) - Rasio rega marang wutah bathi resik|Exelixis Corp - Pangali rega marang bathi tumrap wutah|Nuvalent Therapeutics (NUVL) - Rega marang bathi kanthi panyesuaian wutah|KYMR: Pangali rega marang bathi tumrap wutah|Koefisien bali modal nimbang wutah IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Pangali rega marang bathi tumrap wutah|ORIC: Rasio nilai perusahaan marang wutah bathi|RLAY (Relay Pharma) - Pangali PEG|Pangali PEG Nurix Corp|Rasio rega marang bathi tumrap wutah Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Koefisien bali modal nimbang wutah|Pangali PEG CGEM (Cullinan Therapeutics, Inc.)|Rasio rega marang wutah bathi resik Immuneering Corp|C4 Tx - Pangali PEG|Rega marang bathi kanthi panyesuaian wutah Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Pangali rega marang bathi tumrap wutah|PMVP: Rasio nilai perusahaan marang wutah bathi|KPTI (Karyopharm Therapeutics, Inc.) - Pangali PEG|Rega marang bathi kanthi panyesuaian wutah Propanc Biopharma, Inc. PPCB|Pangali PEG BGMS|aadibio.com - Rasio P/E diaturake wutah|Aileron Therapeutics, Inc. - Pangali rega marang bathi tumrap wutah|Koefisien bali modal nimbang wutah BPMC|GLYC: Pangali rega marang bathi tumrap wutah|SpringWorks Therapeutics Inc. - Rasio nilai perusahaan marang wutah bathi